Tyrosine kinase inhibitors. Therapies for thyroid cancer

Authors :: Silvia Martina Ferrari
Poupak Fallahi
Enke Baldini
Salvatore Ulisse
Gabriele Materazzi
Paolo Miccoli
Alessandro Antonelli
Publication Year :: 2016
Publisher :: Bentham e Books, 2016.

Subjects :: telomerase reverse transcriptase (TERT) mutations
N-RAS mutations
vandetanib
H-RAS mutations
Anaplastic thyroid cancer, BRAF mutations, cabozantinib, CLM3, CLM94, differentiated thyroid cancer, follicular thyroid cancer, H-RAS mutations, K-RAS mutations, lenvantinib, medullary thyroid cancer, N-RAS mutations, papillary thyroid cancer, pyrazolpyrimidine, Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, RET mutations, sorafenib, telomerase reverse transcriptase (TERT) mutations, vandetanib, vascular endothelial growth factor receptor 2
follicular thyroid cancer
pyrazolpyrimidine
differentiated thyroid cancer
Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements
RET mutations
Anaplastic thyroid cancer
CLM3
BRAF mutations
medullary thyroid cancer
Thyroid cancer
cabozantinib
CLM94
vascular endothelial growth factor receptor 2
K-RAS mutations
lenvantinib
Thyroid cancer, Therapy, Tyrosin kinase inhibitors
papillary thyroid cancer
sorafenib
Therapy
Tyrosin kinase inhibitors

Tools